Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen (GSK3228836) for Chronic Hepatitis B (B-Clear, Japan cohort)
jRCT2080225311Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of bepirovirsen in Chronic Hepatitis B (CHB) (3 arms), sponsored by GSK. Primary endpoint: HBsAg and HBV DNA loss at 24 weeks post-treatment. Started Aug 2020; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080225311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225311.